Alopecia as an Emerging Adverse Effect Associated with Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss: A Scoping Review

    August 2025 in “ Cureus ”
    Rosa López-Gigosos, David Barrera, Marı́a Muñoz, M. Díaz
    Studysummary This review indicates that glucagon-like peptide-1 receptor agonists may be linked to hair loss, raising safety concerns despite the lack of definitive causal evidence.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on cureus.com →
    Discuss this study in the Community →

    Research cited in this study 6

    1. Exploring the Hair Loss Risk in Glucagon-Like Peptide-1 Agonists: Emerging Concerns and Clinical Implications Journal of the European Academy of Dermatology and Venereology · 2025
    2. Glucagon-Like Peptide-1 Receptor Agonist Medications and Hair Loss: A Retrospective Cohort Study Journal of the American Academy of Dermatology · 2025
    3. Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study Cardiovascular Drugs and Therapy · 2024
    4. GLP-1 Agonists and Hair Loss: A Call for Further Investigation International Journal of Dermatology · 2024
    5. Telogen Effluvium Associated with Weight Loss: A Single Center Retrospective Study Annals of dermatology/Annals of Dermatology · 2024
    6. Assessing the Impact of Alopecia on Quality of Life, Depression, and Self-Esteem in Saudi Arabia Curēus · 2023